Lymphoma PDX Models

Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The CrownBio lymphoma PDX collection consists of many models, including both primary and metastatic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL CANCER TYPE SUBTYPE models per page
LY0257LymphomaNHL (DLBCL, ABC, MYD88 L265P)VIEW MODEL
LY14019LymphomaNHLVIEW MODEL
LY2118LymphomaEBV transformed lymphomaVIEW MODEL
LY2214LymphomaNHL (DLBCL, GCB)VIEW MODEL
LY2219LymphomaEBV transformed lymphomaVIEW MODEL
LY2240LymphomaEBV transformed lymphomaVIEW MODEL
LY2264LymphomaNHL (DLBCL, ABC, MYD88 L265P)VIEW MODEL
LY2266LymphomaNHL (B cell, ABC/GCB)VIEW MODEL
LY2298LymphomaB cell lymphoma (ABC/GCB, MYD88 L265P)VIEW MODEL
LY2301LymphomaNHL (DLBCL, ABC)VIEW MODEL